CogEcig: Cognitive Functioning and Electronic Cigarette
NCT ID: NCT01735487
Last Updated: 2012-12-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
20 participants
INTERVENTIONAL
2012-09-30
2012-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
On the first study day, participants will be randomised to use one of five ordered conditions: Electronic Nicotine Delivery Device (ENDD) (fourth generation) containing nicotine 2,4%; Electronic Nicotine Delivery Device (ENDD (second generation) containing nicotine 7,4 mg; Electronic Nicotine Delivery Device (ENDD containing nicotine 9 mg; Electronic Nicotine Delivery Device (ENDD nicotine free; their usual cigarette. Additionally participants will be trained to use an electronic cigarette. The following tests will be completed at the each visits: Continuous Performance Test - AX version (CPT-AX), Wisconsin card sorting test( WCST), Working memory test (N-BACK).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Own Brand cigarette
Smoke Own Brand cigarette, 15 puff of cigarette.
one high 2,4% nicotine
Smoke, 25 puff, of electronic cigarette one high 2,4% nicotine
original 7,4 mg nicotine
Smoke, 15 puff, of Categoria electronic cigarette 7,4 mg nicotine
nicotine free
smoke, 15 puff, of electronic cigarette nicotine free
Ego 9mg
smoke, 15 puff, of electronic cigarette Ego 9 mg
One High 2,4% nicotine
Smoke electronic cigarette One High 2,4% nicotine for a day, 15 puff of e-cigarette.
Own Brand cigarette
Smoke, 15 puff of, Own Brand cigarettes;
original 7,4 mg nicotine
Smoke, 15 puff, of Categoria electronic cigarette 7,4 mg nicotine
nicotine free
smoke, 15 puff, of electronic cigarette nicotine free
Ego 9mg
smoke, 15 puff, of electronic cigarette Ego 9 mg
Original 7,4 mg nicotine
Smoke electronic cigarette Original 7,4 mg nicotine for a day. 15 puff of e-cigarette.
Own Brand cigarette
Smoke, 15 puff of, Own Brand cigarettes;
one high 2,4% nicotine
Smoke, 25 puff, of electronic cigarette one high 2,4% nicotine
nicotine free
smoke, 15 puff, of electronic cigarette nicotine free
Nicotine Free
Smoke electronic cigarette nicotine free (15 puff)
Own Brand cigarette
Smoke, 15 puff of, Own Brand cigarettes;
one high 2,4% nicotine
Smoke, 25 puff, of electronic cigarette one high 2,4% nicotine
original 7,4 mg nicotine
Smoke, 15 puff, of Categoria electronic cigarette 7,4 mg nicotine
Ego 9mg
smoke, 15 puff, of electronic cigarette Ego 9 mg
EGO 9mg
Smoke electronic cigarette EGO for a day (15 puff)
Own Brand cigarette
Smoke, 15 puff of, Own Brand cigarettes;
one high 2,4% nicotine
Smoke, 25 puff, of electronic cigarette one high 2,4% nicotine
original 7,4 mg nicotine
Smoke, 15 puff, of Categoria electronic cigarette 7,4 mg nicotine
nicotine free
smoke, 15 puff, of electronic cigarette nicotine free
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Own Brand cigarette
Smoke, 15 puff of, Own Brand cigarettes;
one high 2,4% nicotine
Smoke, 25 puff, of electronic cigarette one high 2,4% nicotine
original 7,4 mg nicotine
Smoke, 15 puff, of Categoria electronic cigarette 7,4 mg nicotine
nicotine free
smoke, 15 puff, of electronic cigarette nicotine free
Ego 9mg
smoke, 15 puff, of electronic cigarette Ego 9 mg
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* pregnancy,
* breastfeeding,
* blood pressure \> 180 mm Hg systolic and/or 100 mm Hg diastolic,
* weight \< 45 or \> 120 kg, or
* current use of any other smoking cessation medications
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universita degli Studi di Catania
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Riccardo Polosa
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centro per la Prevenzione e Cura del Tabagimso
Catania, Italy, Italy
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Caponnetto P, Maglia M, Cannella MC, Inguscio L, Buonocore M, Scoglio C, Polosa R, Vinci V. Impact of Different e-Cigarette Generation and Models on Cognitive Performances, Craving and Gesture: A Randomized Cross-Over Trial (CogEcig). Front Psychol. 2017 Mar 9;8:127. doi: 10.3389/fpsyg.2017.00127. eCollection 2017.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CogEcig
Identifier Type: -
Identifier Source: org_study_id